TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06393751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolinapant
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolinapant
Description: Given PO
Study: NCT05689658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brazilian Diabetes Prevention Program
Description: A Program structured in 7 visits (in group and individual) to guide the improvement of diet quality, self-care, and practice of physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Hypocaloric diet prescription
Study: NCT05650073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive soundscapes
Description: Audio technology used to create a three-dimensional sound experience in which the user is immersed in a virtual soundscape
Study: NCT04513834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GP will receive the educational outreach visit by a DAM (healthcare representative).
Description: GP will receive the educational outreach visit by a DAM (healthcare representative).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GP will receive the educational outreach visit by a DAM (healthcare representative).
Description: GP will receive the educational outreach visit by a DAM (healthcare representative).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education material on PPI deprescribing will be sent to the patients
Description: Patient education material on PPI deprescribing will be sent to the patients
Study: NCT05829616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS12004
Description: Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
Study: NCT06536764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercises
Description: Progressive muscle Relaxation exercises will be performed by this group.Advise women to sit in chair. The therapist's voice will then instruct them to contract and release different muscle groups. They will practice tensing a muscle group until they feel the slight contraction and then release it, simultaneously contracting and relaxing all other muscle groups.Practice will progress in the same manner, starting with the muscles in the feet, then the calf, thigh, gluteal muscles, abdomen, chest, hands, forearms, arms, shoulders, neck, face, and finally the forehead muscles .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy(Hot pack,TENS,Patient Education)
Description: Conventional therapy including hot pack and TENS will be applied for 10 minutes each. Meanwhile, patients will be given education to ease back pain and improve sleep.
Study: NCT05365776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exposure Therapy
Description: Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed aerobic exercise
Description: Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through email message support.
Study: NCT06427967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Dream Team
Description: Five total sessions, 60-minutes each, with one session every 7 days (+/- 21 days between sessions), Session activities include discussion prompts, interactive learning methods, skill rehearsals, mindfulness / somatic exercises and lecture slides facilitated by a trained facilitator.
Study: NCT05004935

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beetroot juice
Description: single intake of beetroot juice containing 800mg nitrates

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nitrate
Description: single intake of 800mg nitrates
Study: NCT05216120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib 4.5 MG
Description: Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food.
Study: NCT06612034

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No Intervention: Observational Cohort
Study: NCT06615843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants will receive post-emergency gynecological follow-up at home using a connected health app
Description: The app will facilitate data collection and communication, including logging of vital signs, symptoms (such as pain, bleeding, and vomiting), and uploading of test results. Medical professionals will review the health data twice daily and provide care instructions through instant messaging. The app will also alert the medical team of any urgent updates or deviations from expected health patterns
Study: NCT06546839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPSIPB blcok
Description: A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAPB block
Description: In the lateral decubitus position, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane concerning the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be injected for correction. Following confirmation of the correct position of the needle, 30 ml %0.25 bupivacaine will be administered for the block.
Study: NCT06616129

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Geriatric assessment
Description: At the clinic further information on the somatic, social, psychological and functional domain will be gathered by the nurse and two validated tests to map the vulnerability and resilience of the patient will be used; the Cognitive Impairment Test and the timed Up and Go Test.
Study: NCT06546839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT06616129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision-making conversation
Description: The nurse and nurse practitioner together will talk with the patient and their partner about possible treatment options as well as patients' expectations, preferences and their life in general.~During the conversation the OPT (Outcome Prioritization Tool) will be used to clarify the most important goals of treatment for the patient. The OPT exists of four universal treatment goals rated on a visual analogue scale from 0 to 100. The goals represented are: life extension, maintaining independence, reducing pain and reducing other symptoms. The goals will be explained and the patient will be asked to rate each outcome according to the trade-off principle meaning that two outcomes cannot be rated equally.
Study: NCT06469112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: The device was used to provide vibration with the participants in this group. This device, designed as a combination of cold application and local vibration to reduce pain experienced during invasive procedures, is frequently chosen for all age groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The device was used with participants in this group. The device, at room temperature, was placed by the researcher 5cm proximal to the injection site before the injection was performed. With participants in this group, the device was placed on the procedure site, but no vibration was made. The device was held on the participants for one minute before the injection and throughout the procedure, with the vibration switched off.
Study: NCT05975983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS018_055
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral
Study: NCT04889209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Formulated to contain 5x10\^10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Formulated to contain 5x10\^10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Formulated to contain 5x10\^10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).
Study: NCT06715813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pelvic floor strengthening
Description: pelvic floor strengthening exercises includes :~1. breathing exercises,~2. kegels exercises~3. bridging exercises~4. squatting~5. Elevator exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor strengthening
Description: pelvic floor strengthening exercises includes :~1. breathing exercises,~2. kegels exercises~3. bridging exercises~4. squatting~5. Elevator exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominal strengthening
Description: core stabilization exercises for 2 weeks like stomach hallowing , dead bugs and pelvic tilt exercises and after 2 weeks dead bug progression, planks
Study: NCT06707922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
Description: Peginterferon α-2b Injection, subcutaneous injection, once a week. Tenofovir Alafenamide Fumarate, Oral administration, once a day.
Study: NCT06715228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: shitali pranayama respiratory rehabilitation training
Description: in this group, patients (n=20) with obstructive sleep apnea will participate and will administer six cycles of 5-min shitali respiratory pranayama exercise rehabilitation training (the rehabilitation will be repeated or applied at morning, afternoon, and also at evening) for 12 week as a daily performance
Study: NCT06710925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM001
Description: single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose intramuscular injection
Study: NCT06747286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Game Simulation
Description: A virtual computer game that enables participation in a clinical scenario to measure competence.
Study: NCT06751277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
Description: QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
Study: NCT06226714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV4
Description: 1 dose of MCV4 on Day 0
Study: NCT04889209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).
Study: NCT04885621

Intervention type: DIETARY_SUPPLEMENT
Intervention: nutrisystem-D
Description: Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions
Study: NCT04889209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV). Doses are either 0.25 mL or 0.5 mL.
Study: NCT06226714

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MPSV4
Description: 1 dose of MSPV4 on Day 0
Study: NCT04889209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV). Doses are either 0.25 mL or 0.5 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV). Doses are either 0.25 mL or 0.5 mL.
Study: NCT04222959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls Invest Intervention
Description: App-based trainings: The first 2 modules cover gender and cultural norms related to girls' social and economic empowerment, increasing girls' recognition of the importance of financial literacy and independence. The last 3 modules cover finance, educational loans, and employment.~Savings account: Participants receive $100 deposited into a savings account we set up for them, conditional upon completion of app-based trainings.
Study: NCT06410157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily practice
Description: Participants will be asked to undergo daily mindfulness practice while regulating (either increase or decrease) heart rate oscillation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily practice
Description: Participants will be asked to undergo daily mindfulness practice while regulating (either increase or decrease) heart rate oscillation.
Study: NCT06311669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iliac vein stenting
Description: patients will undergo left common iliac vein stenting according to diameter measurements using balloon-mounted stents.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iliac vein stenting
Description: patients will undergo left common iliac vein stenting according to diameter measurements using balloon-mounted stents.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic vein embolization
Description: embolization of pelvic veins by injection of left ovarian vein or parauterine veins pelvic escape points using sandwich technique of detachable or pushable coils and polidocanol 3 %.
Study: NCT05307406

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimental
Description: Participants will receive a single IV infusion in a double blind manner

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Participants will receive a single IV infusion in a double blind manner
Study: NCT06505460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study: NCT06518304

Intervention type: OTHER
Group type: OTHER
Intervention: GentleWave
Description: GentleWave System employs a degassing process that removes dissolved gases from the solution. This optimization prevents the vapor-lock effect and ensures effective energy transmission through the root canal. As the solution enters the pulp chamber, hydrodynamic cavitation occurs, creating microbubbles that implode and generate sound waves across a broad frequency spectrum

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Protocol
Description: Delivers irrigants (NaOCl, EDTA) through a needle-syringe system, often fails to reach the entire working length. This inadequacy can result in residual bacteria and necrotic tissue, potentially compromising treatment efficacy and increasing the risk of treatment failure.
Study: NCT06537388

Intervention type: PROCEDURE
Intervention: Ventilation type
Description: Type of ventilation used during the EBUS procedure, either HFJV or IPPV
Study: NCT06469801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperfine
Description: Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO. Patients will undergo imaging within 24 hours of ECMO initiation/cannulation. Patients that remain on ECMO will have repeat imaging at 72-120 hours of ECMO therapy and again weekly for the duration of their ECMO course. Patients will also undergo a portable MRI within 24 hours of clinical head imaging, if applicable.
Study: NCT04767321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 gel, 3% w/w
Description: LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
Study: NCT06311357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Ensure 6 scoops dietary supplement powder in 250 ml of water, 2 drinks per days for 12 weeks.
Study: NCT06304857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg tablet q.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet matching dapagliflozin 10 mg q.d